bremelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-18 and is reviewed periodically as new material appears.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
To enforce the amendment, Congress passed the National Prohibition Act, also known as the Volstead Act. The Prohibition Bureau Narcotics Division, which enforced the Harrison Act, was overseen by Levi G. Nutt, the 1st narcotics commissioner of the United States. By the 1930s, the policy was seen as a failure: production and consumption of alcohol persisted, organized crime flourished in the alcohol black market, and tax revenue, particularly needed after the start of the Great Depression in 1929, was lost. Prohibition was repealed by passage of the 21st Amendment in 1933, with President Franklin D. Roosevelt (1933–1945) asking Americans not to abuse "this return to personal freedom." In 1922, the Narcotic Drugs Import and Export Act broadened federal regulation of opiates and coca products by prohibiting import and export for non-medical use, and established the Federal Narcotics Control Board (FNCB) to administrate.
== Contribution to Chemistry == The enduring contributions of Zervas were made together with Bergmann and involved the first successful synthesis of substantial length oligopeptides. They achieved this using the carboxybenzyl amine protecting group for the masking of the N-terminus of the growing oligopeptide chain to which amino acid residues are added in a serial manner. The carboxybenzyl group discovered by Zervas is introduced by reaction with benzyl chloroformate, originally in aqueous sodium carbonate solution at 0 °C:
== Recreational use == As dihydrocodeine can provide a euphoric high when taken in higher-than-therapeutic doses, it is quite commonly used recreationally. The typical recreational dose can be anything from 70 mg to 500 mg, or, in users with tolerance, even more. Potentiators and adjuvants are often included when dihydrocodeine is used in an unsupervised fashion, especially carisoprodol, glutethimide, hydroxyzine and first-generation antihistamines, both to intensify the effect and lessen side-effects such as itching.
The oral bioavailability of amphetamine varies with gastrointestinal pH; it is well absorbed from the gut, and bioavailability is typically 90%. Amphetamine is a weak base with a pKa of 9.9; consequently, when the pH is basic, more of the drug is in its lipid soluble free base form, and more is absorbed through the lipid-rich cell membranes of the gut epithelium. Conversely, an acidic pH means the drug is predominantly in a water-soluble cationic (salt) form, and less is absorbed. Between 16-20% of amphetamine circulating in the bloodstream is bound to plasma proteins. Following absorption, amphetamine readily distributes into most tissues in the body, with high concentrations occurring in cerebrospinal fluid and brain tissue. The half-lives of amphetamine enantiomers differ and vary with urine pH. At normal urine pH, the half-lives of dextroamphetamine and levoamphetamine are 9–11 hours and 11–14 hours, respectively. Highly acidic urine will reduce the enantiomer half-lives to 7 hours; highly alkaline urine will increase the half-lives up to 34 hours. The immediate-release and extended release variants of salts of both isomers reach peak plasma concentrations at 3 hours and 7 hours post-dose respectively. Amphetamine is eliminated via the kidneys, with 30–40% of the drug being excreted unchanged at normal urinary pH. When the urinary pH is basic, amphetamine is in its free base form, so less is excreted.
=== List of superintendents === Shawn Joseph (interim 2025–2026; 2026-present) Millard House II (2023–2025) Monica Goldson, CEO (interim 2018–2019; 2019–2023) Kevin M. Maxwell, CEO (2013–2018) Alvin Crawley (interim 2012–2013) William R. Hite, Jr. (interim 2008–2009; 2009–2012) John E. Deasy (2006–2008) Howard A. Burnett (interim 2005–2006) André J. Hornsby (2003–2005) Iris T. Metts (1999–2003) Jerome Clark (1995–1999) Edward M. Felegy (1991–1995) John A. Murphy (1984–1991) Edward J. Feeney (1976–1984) Carl W. Hassel (1970–1976) William S. Schmidt (1951–1970) G. Gardner Shugart (1944–1951) Nicholas Orem Sr. (1921–1943) E.S. Burroughs (1915–1921) Frederick Sasscer Jr. (1902–1914)
Sources: en.wikipedia.org
== History == The mesentery has been known for thousands of years, however it was unclear whether the mesentery is a single organ, or whether there are several mesenteries. The classical anatomical description of the mesocolon is credited to British surgeon Sir Frederick Treves in 1885, although a description of the membrane as a single structure dates back to at least Leonardo da Vinci. Treves is known for performing the first appendectomy in England in 1888; he was surgeon to both Queen Victoria and King Edward VII. He studied the human mesentery and peritoneal folds in 100 cadavers and described the right and left mesocolons as vestigial or absent in the human adult. Accordingly, the small intestinal mesentery, transverse, and sigmoid mesocolons all terminated or attached at their insertions into the posterior abdominal wall. These assertions were included in mainstream surgical, anatomical, embryological, and radiologic literature for more than a century. Almost 10 years before Treves, the Austrian anatomist Carl Toldt described the persistence of all portions of the mesocolon into adulthood. Toldt was professor of anatomy in Prague and Vienna; he published his account of the human mesentery in 1879. Toldt identified a fascial plane between the mesocolon and the underlying retroperitoneum, formed by the fusion of the visceral peritoneum of the mesocolon with the parietal peritoneum of the retroperitoneum; this later became known as Toldt's fascia.
MOF-177, a MOF designed for CO2 capture, has a heat capacity of 0.5 J/(g⋅K) at ambient temperature. The companies Svante is commercialising CALF-20 for CO2 capture and Captivate Technology is using MUF-16.
HA (aq) + H2O (l) ⇌ H3O+ (aq) + A− (aq) Ka Common examples of monoprotic acids in mineral acids include hydrochloric acid (HCl) and nitric acid (HNO3). On the other hand, for organic acids the term mainly indicates the presence of one carboxylic acid group and sometimes these acids are known as monocarboxylic acid. Examples in organic acids include formic acid (HCOOH), acetic acid (CH3COOH) and benzoic acid (C6H5COOH).
From 15 to 20 February, the Battle of Wadi al-Batin took place inside Iraq; this was the first of two attacks by 1 Battalion 5th Cavalry of the 1st Cavalry Division. It was a feint attack, designed to make the Iraqis think that a coalition invasion would take place from the south. The Iraqis fiercely resisted, and the Americans eventually withdrew as planned back into the Wadi al-Batin. Three US soldiers were killed and nine wounded, with one M2 Bradley IFV turret destroyed, but they had taken 40 prisoners and destroyed five tanks, and successfully deceived the Iraqis. This attack led the way for the XVIII Airborne Corps to sweep around behind the 1st Cav and attack Iraqi forces to the west. On 22 February 1991, Iraq agreed to a Soviet-proposed ceasefire agreement. The agreement called for Iraq to withdraw troops to pre-invasion positions within six weeks following a total ceasefire, and called for monitoring of the ceasefire and withdrawal to be overseen by the UN Security Council. The coalition rejected the proposal, but said that retreating Iraqi forces would not be attacked, and gave 24 hours for Iraq to withdraw its forces. On 23 February, fighting resulted in the capture of 500 Iraqi soldiers. On 24 February, British and American armored forces crossed the Iraq–Kuwait border and entered Iraq in large numbers, taking hundreds of prisoners. Iraqi resistance was light, and four Americans were killed.
A researcher at Texas AgriLife Research reported in 2012 that incorporating two genes from spinach into citrus trees improved resistance to citrus greening disease in greenhouse trials. Field tests by Southern Gardens Citrus of oranges with the spinach genes in Florida are ongoing. A resistant variety of mandarin orange called 'Bingo' has been bred at the University of Florida. Some other varieties have a partial tolerance to the disease.
Sources: en.wikipedia.org
=== Irritable bowel syndrome === There is evidence that a dietician-supervised low-FODMAP diet is the best available way to control IBS symptoms, though there is a lack of evidence on possible adverse effects. The beneficial effect of low-FODMAP for people with IBS may be related to reduced osmotic load in the gut or changes in gut-brain axis signaling. The low-FODMAP diet does not cause any significant change in the gut microbiota in people with IBS. The effectiveness of low-FODMAP diet in children with IBS is unclear. While restrictive diets like the low-FODMAP diet can help manage symptoms in patients with Irritable bowel syndrome, they pose a significant danger: they can increase the patient's risk of developing disordered eating. The initial success in symptom reduction may become a dangerous obsession with controlling food, potentially leading to conditions such as ARFID or Orthorexia nervosa. These issues severely impact clinical outcomes and quality of life, and worsen overall health. Early monitoring and intervention are crucial to catching and addressing these pathological eating patterns.
Other impacts on exposure in utero PFOA exposure on thyroid function has also been a topic of concern, and has found to negatively impact thyroid stimulating hormone even at low levels when exposed during fetal development. PFOA is also shown to have obesogenic effects, and an experimental study found a positive correlation to low-dose prenatal exposure of PFOA and prevalence of overweight and high waist circumference in females at age 20. A correlation between in utero PFOA exposure and mental performance has yet to be established, as many studies have resulted in insignificant results. For example, a study conducted near Parkersburg, West Virginia did not find a significant association between in utero PFOA exposure and performance of math skills or reading performance in children ages 6 to 12 living in the PFOA-contaminated water district. Based on a cohort study conducted in the Mid-Ohio Valley, no clear association was found between prenatal exposure to PFOA and birth defects, although a possible association with brain defects was observed and requires further research and assessment. Extrapolated epidemiological data suggests a slight association between PFOA exposure and low birth weight. This was consistent based on blood levels of PFOA metabolites regardless of the geographic residence of subjects. Generally, the findings among human fetuses exposed to the chemical were considerably less drastic than what was seen in mice studies. Because of this, studies linking exposure to low birth weight can be considered inconclusive.
The Maryland Housing Certainty Act and Maryland Transit and Housing Opportunity Act both passed, but Moore's third bill, the Starter and Silver Homes Act, failed to advance out of committee. Moore signed the two housing bills into law in May 2026.
Candida Histoplasmosis Dandruff Prion - Misfolded proteins that usually occur in the brain and trigger other normal proteins to misfold. They are extremely rare, and these built-up proteins lead to complications.
There are two commonly cultivated strains which are known to be distinct. One is the strain that was collected in 1962 by ecologist and psychologist Sterling Bunnell (the Bunnell strain), colloquially mis-attributed as the Wasson-Hofmann strain. The other was collected from Huautla de Jiménez in 1991 by anthropologist Bret Blosser (the Blosser or Palatable strain). There are other strains that are not as well documented, such as the Luna strain (possibly Bunnell) isolated from a Hawaiian patch of Salvia divinorum clones, featuring unusually serrated and rounded rather than ovate leaves.
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.